amifostine anhydrous has been researched along with Kidney Diseases in 31 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared to dexrazoxane, amifostine provided a comparable degree of protection against the nephrotoxicity of doxorubicin, but was less cardioprotective and did not prevent the mortality and loss of body weight produced by doxorubicin." | 3.70 | Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats. ( Chadwick, DP; Ferrans, VJ; Herman, EH; Zhang, J, 2000) |
| "Also grade III or IV infections (P=0." | 2.71 | A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. ( Chow, H; Chuah, CT; Fook, SC; Goh, YT; Hwang, WY; Koh, LP; Ng, HJ; Tan, CH; Tan, KW; Tan, PH; Wong, C, 2004) |
| "Thirty-one patients with solid tumors stratified according to pretreatment were randomized to receive cisplatin/ifosfamide-based chemotherapy with or without amifostine (1000 mg absolute) given as a short infusion prior to cisplatin." | 2.69 | The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. ( Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolte, H; van Vangerow, A, 2000) |
| "Cisplatin is not directly toxic to bone, but cisplatin nephrotoxicity leading to magnesium wasting may affect magnesium and calcium metabolism, both of which contribute to bone integrity." | 2.42 | Cisplatin nephrotoxicity affects magnesium and calcium metabolism. ( Goren, MP, 2003) |
| " It was shown that this compound can protect normal cells from the toxic effects of ionizing radiation and chemotheraphy without affecting the efficacy of the therapy." | 2.39 | [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy]. ( Chomiczewski, K; Jabłońska, H; Wrembel-Wargocka, J, 1996) |
| "Cisplatin is a nephrotoxic drug; however, agents that may make cisplatin therapy more safe and rewarding will be available in the near future." | 2.38 | Newer insights into cisplatin nephrotoxicity. ( Anand, AJ; Bashey, B, 1993) |
| " Therapeutic strategies aimed at reducing toxicity and allowing dose escalation of intravenous cisplatin, such as administration in hypertonic saline and pharmacokinetically based dosing schedules, have been partially successful in reducing nephrotoxicity and bone marrow suppression." | 2.38 | Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate. ( DeGregorio, MW; Gandara, DR; Makuch, RW; Perez, EA; Wiebe, VJ, 1990) |
| " The aim of our study was to investigate amifostine effects on doxorubicin-induced toxic changes in rats." | 1.48 | The Efficacy of Amifostine against Multiple-Dose Doxorubicin-Induced Toxicity in Rats. ( Bokonjić, D; Dobrić, S; Dragojević-Simić, V; Jaćević, V; Kovačević, A; Kuča, K; Nepovimova, E; Tatomirović, Ž; Vališ, M, 2018) |
| " Despite this, none of the adverse effects of 0." | 1.35 | In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro. ( Baverel, G; Dubourg, L; Michoudet, C; Yaseen, Z, 2008) |
| "Sodium selenite was ineffective in reducing tetraplatin-induced damage when administered 4 hr before tetraplatin at doses of 0." | 1.28 | Reduction of tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat. ( Carfagna, PF; Chaney, SG; Chang, J; Holbrook, DJ, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.90) | 18.7374 |
| 1990's | 11 (35.48) | 18.2507 |
| 2000's | 13 (41.94) | 29.6817 |
| 2010's | 2 (6.45) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 1 |
| Qin, X | 1 |
| Yang, Y | 1 |
| Li, J | 1 |
| Li, X | 1 |
| Zou, X | 1 |
| Huang, Z | 1 |
| Huang, S | 1 |
| Jaćević, V | 1 |
| Dragojević-Simić, V | 1 |
| Tatomirović, Ž | 1 |
| Dobrić, S | 1 |
| Bokonjić, D | 1 |
| Kovačević, A | 1 |
| Nepovimova, E | 1 |
| Vališ, M | 1 |
| Kuča, K | 1 |
| Caloglu, M | 2 |
| Yurut-Caloglu, V | 2 |
| Durmus-Altun, G | 1 |
| Oz-Puyan, F | 1 |
| Ustun, F | 1 |
| Cosar-Alas, R | 1 |
| Saynak, M | 2 |
| Parlar, S | 2 |
| Turan, FN | 1 |
| Uzal, C | 2 |
| Cosar, R | 1 |
| Eskiocak, S | 1 |
| Ozen, A | 1 |
| Altaner, S | 1 |
| Ibis, K | 1 |
| Turan, N | 1 |
| Denizli, B | 1 |
| Uregen, B | 1 |
| Kocak, Z | 1 |
| Goren, MP | 1 |
| Hwang, WY | 1 |
| Koh, LP | 1 |
| Ng, HJ | 1 |
| Tan, PH | 1 |
| Chuah, CT | 1 |
| Fook, SC | 1 |
| Chow, H | 1 |
| Tan, KW | 1 |
| Wong, C | 1 |
| Tan, CH | 1 |
| Goh, YT | 1 |
| Fisher, MJ | 1 |
| Lange, BJ | 1 |
| Needle, MN | 1 |
| Janss, AJ | 1 |
| Shu, HK | 1 |
| Adamson, PC | 1 |
| Phillips, PC | 1 |
| Gallegos-Castorena, S | 1 |
| Martínez-Avalos, A | 1 |
| Mohar-Betancourt, A | 1 |
| Guerrero-Avendaño, G | 1 |
| Zapata-Tarrés, M | 1 |
| Medina-Sansón, A | 1 |
| Zhang, J | 2 |
| Wang, X | 1 |
| Lu, H | 1 |
| Yaseen, Z | 1 |
| Michoudet, C | 1 |
| Baverel, G | 1 |
| Dubourg, L | 1 |
| Glover, D | 2 |
| Glick, JH | 2 |
| Weiler, C | 2 |
| Yuhas, J | 1 |
| Kligerman, MM | 2 |
| Yuhas, JM | 1 |
| Spellman, JM | 1 |
| Jordan, SW | 1 |
| Pardini, MC | 1 |
| Afzal, SM | 1 |
| Culo, F | 1 |
| Anand, AJ | 1 |
| Bashey, B | 1 |
| Wrembel-Wargocka, J | 1 |
| Jabłońska, H | 1 |
| Chomiczewski, K | 1 |
| Selvaratnam, G | 1 |
| Philips, RH | 1 |
| Mohamed, AK | 1 |
| Radzi, A | 1 |
| Hausheer, FH | 1 |
| Kanter, P | 1 |
| Cao, S | 1 |
| Haridas, K | 1 |
| Seetharamulu, P | 1 |
| Reddy, D | 1 |
| Petluru, P | 1 |
| Zhao, M | 1 |
| Murali, D | 1 |
| Saxe, JD | 1 |
| Yao, S | 1 |
| Martinez, N | 1 |
| Zukowski, A | 1 |
| Rustum, YM | 1 |
| Lindemann, K | 1 |
| Capizzi, RL | 1 |
| Weichert-Jacobsen, KJ | 1 |
| Bannowski, A | 1 |
| Küppers, F | 1 |
| Loch, T | 1 |
| Stöckle, M | 1 |
| Herman, EH | 1 |
| Chadwick, DP | 1 |
| Ferrans, VJ | 1 |
| Hartmann, JT | 2 |
| Knop, S | 2 |
| Fels, LM | 2 |
| van Vangerow, A | 1 |
| Stolte, H | 2 |
| Kanz, L | 2 |
| Bokemeyer, C | 2 |
| Cronin, S | 1 |
| Uberti, JP | 1 |
| Ayash, LJ | 1 |
| Raith, C | 1 |
| Ratanatharathorn, V | 1 |
| von Vangerow, A | 1 |
| Vaira, M | 1 |
| Barone, R | 1 |
| Aghemo, B | 1 |
| Mioli, PR | 1 |
| De Simone, M | 1 |
| Cui, H | 1 |
| Zhang, S | 2 |
| Li, P | 1 |
| Guan, Z | 1 |
| Sun, X | 1 |
| Shen, K | 1 |
| Wu, M | 1 |
| Hu, X | 1 |
| Liu, S | 1 |
| Di, L | 1 |
| Gandara, DR | 2 |
| Perez, EA | 2 |
| Weibe, V | 1 |
| De Gregorio, MW | 1 |
| Carfagna, PF | 1 |
| Chaney, SG | 1 |
| Chang, J | 1 |
| Holbrook, DJ | 1 |
| Tognella, S | 1 |
| Wiebe, VJ | 1 |
| Makuch, RW | 1 |
| DeGregorio, MW | 1 |
| Fox, K | 1 |
| Turrisi, A | 1 |
| Hirschel-Scholz, S | 1 |
| Caverzasio, J | 1 |
| Bonjour, JP | 1 |
9 reviews available for amifostine anhydrous and Kidney Diseases
| Article | Year |
|---|---|
Cisplatin nephrotoxicity affects magnesium and calcium metabolism.
Topics: Adult; Amifostine; Antineoplastic Agents; Calcium; Child; Cisplatin; Clinical Trials as Topic; Human | 2003 |
Newer insights into cisplatin nephrotoxicity.
Topics: Amifostine; Animals; Cisplatin; Furosemide; Glutathione; Humans; Kidney Diseases; Male; Mannitol; So | 1993 |
[Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
Topics: Amifostine; Antineoplastic Agents; Hematologic Diseases; Humans; Kidney Diseases; Neoplasms; Nervous | 1996 |
Adverse effects of cytotoxics-platinum agents.
Topics: Amifostine; Antineoplastic Agents; Carboplatin; Cisplatin; Humans; Kidney Diseases; Neoplasms; Perip | 1997 |
Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
Topics: Amifostine; Animals; Antineoplastic Agents; Cisplatin; Drug Interactions; Humans; Kidney Diseases; M | 1998 |
Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Topics: Amifostine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1999 |
Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Topics: Adrenocorticotropic Hormone; Amifostine; Anticonvulsants; Cisplatin; Ditiocarb; Humans; Inactivation | 1991 |
Pharmacological interventions to reduce platinum-induced toxicity.
Topics: Adrenocorticotropic Hormone; Amifostine; Cisplatin; Ditiocarb; Fluid Therapy; Glutathione; Hematolog | 1990 |
Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.
Topics: Amifostine; Antidotes; Cisplatin; Ditiocarb; Drug Therapy, Combination; Humans; Kidney Diseases; Thi | 1990 |
7 trials available for amifostine anhydrous and Kidney Diseases
| Article | Year |
|---|---|
A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Female; Graft Surviva | 2004 |
Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Drug | 2004 |
Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin.
Topics: Adolescent; Amifostine; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2007 |
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfa | 2000 |
A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2001 |
[Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Topics: Amifostine; Antineoplastic Agents; Carcinoma; Cisplatin; Humans; Hyperthermia, Induced; Intraoperati | 2001 |
[Amifostin in protection of kidney from cisplatinum injury].
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Cisplatin; Humans; Kidney Diseases; Middle Aged; Pro | 2002 |
15 other studies available for amifostine anhydrous and Kidney Diseases
| Article | Year |
|---|---|
Ginkgo biloba extract attenuates cisplatin-induced renal interstitial fibrosis by inhibiting the activation of renal fibroblasts through down-regulating the HIF-1α/STAT3/IL-6 pathway in renal tubular epithelial cells.
Topics: Amifostine; Animals; Cisplatin; Culture Media, Conditioned; Epithelial Cells; Fibroblasts; Fibrosis; | 2023 |
The Efficacy of Amifostine against Multiple-Dose Doxorubicin-Induced Toxicity in Rats.
Topics: Amifostine; Animals; Chemical and Drug Induced Liver Injury; Doxorubicin; Kidney Diseases; Male; Org | 2018 |
Histopathological and scintigraphic comparisons of the protective effects of L-carnitine and amifostine against radiation-induced late renal toxicity in rats.
Topics: Amifostine; Animals; Carnitine; Cytoprotection; Drug Evaluation, Preclinical; Female; Kidney; Kidney | 2009 |
Radiation-induced chronic oxidative renal damage can be reduced by amifostine.
Topics: Amifostine; Animals; Antioxidants; Catalase; Chronic Disease; Cobalt Radioisotopes; Female; Glutathi | 2012 |
Amifostine increases cure rate of cisplatin on ascites hepatoma 22 via selectively protecting renal thioredoxin reductase.
Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cell Proliferati | 2008 |
In vivo mesna and amifostine do not prevent chloroacetaldehyde nephrotoxicity in vitro.
Topics: Acetaldehyde; Acetyl Coenzyme A; Adenosine Triphosphate; Amifostine; Animals; Disease Models, Animal | 2008 |
Phase I trials of WR-2721 and cis-platinum.
Topics: Amifostine; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Humans; Kidney Diseases; Neoplasm | 1984 |
Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide.
Topics: Amifostine; Animals; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combin | 1980 |
Administration of the cytoprotectant amifostine.
Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Humans; Kidney | 1998 |
Direct amifostine effect on renal tubule cells in rats.
Topics: Acetylglucosaminidase; Amifostine; Animals; Antineoplastic Agents; Biomarkers; Cisplatin; Kidney Dis | 1999 |
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Doxorubicin; H | 2000 |
Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.
Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin | 2000 |
Reduction of tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat.
Topics: Amifostine; Animals; Antineoplastic Agents; Antiviral Agents; Blood Urea Nitrogen; Creatinine; Ditio | 1990 |
Phase I/II trials of WR-2721 and cis-platinum.
Topics: Amifostine; Cisplatin; Drug Evaluation; Humans; Kidney; Kidney Diseases; Neoplasms; Organothiophosph | 1986 |
Prevention of parathyroid hormone-dependent nephrocalcinosis by chronic administration of the organic phosphorothioate WR-2721.
Topics: Amifostine; Animals; Calcinosis; Calcitriol; Calcium; Cyclic AMP; Glomerular Filtration Rate; Hyperp | 1987 |